Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of GFT505 in atherogenic dyslipidaemia with abdominal obesity
2007-004337-41Phase 2Terminated
- Sponsor
- Genfit
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherogenic dyslipidaemia (AD) and Abdominal adiposity (ABCD) comparing GFT505 30 mg once daily with Placebo once daily (2 arms). Primary endpoints: Primary efficacy endpoints (triglycerides and HDL-C) and Safety endpoints. Started Aug 2007; status: terminated.
02
Drugs
elafibranor
03
Conditions
atherogenic dyslipidaemia (AD)Abdominal adiposity (ABCD)
Beyond the preview
Go deeper on 2007-004337-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004337-41.